MAP1LC3A and cervical cancer: In addition, treated with TBM combination with 3-MA or wortmannin (WTM), the PtdIns3K inhibitors that selectively block activation of Beclin1-Vps34 complex25, obviously decreased LC3 II and LC3 dots formation in cervical cancer cells (Figs. 3c, d; Supplementary Figure 6A and 6B).